Abstract
2/2023
vol. 110
Special paper
Alopecia areata. Diagnostic and therapeutic recommendations of the Polish Society of Dermatology. Part 2: Treatment
- Department of Dermatology, Medical University of Warsaw, Warsaw, Poland
- Department of Dermatology, Medical University of Silesia, Katowice, Poland
- Department of Dermatology, Pediatric and Oncological Dermatology, Medical University of Lodz, Lodz, Poland
- Department of Dermatology, Sexually Transmitted Diseases and Immunology, University of Warmia and Mazury, Olsztyn, Poland
- Department of Cosmetology and Aesthetic Dermatology, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, Poland
Dermatol Rev/Przegl Dermatol 2023, 110, 101–120
Online publish date: 2023/05/26
The treatment goal in alopecia areata is induction of hair regrowth and halting the progression of the disease. Treatment decisions depend on the severity of the alopecia areata as assessed by the Severity of Alopecia Tool (SALT) or the Alopecia Areata Scale (AAS). In mild alopecia areata, very ultra-high potency topical glucocorticoids and intralesional triamcinolone acetonide are the mainstay of treatment. In moderate to severe alopecia areata, systemic treatment is usually required. Currently, the only drug dedicated for alopecia areata, approved in Europe and the United States is baricitinib. Ritlecitinib, a JAK3/TEC inhibitor is approved in the United States for individuals 12 years of age and older with severe alopecia areata and is expected to be approved in Europe soon. Other systemic medications used in alopecia areata include glucocorticoids, cyclosporine, and methotrexate. Contact immunotherapy may be considered. In alopecia areata, long-maintenance treatment is of substantial significance.
Keywords
alopecia areata, baricitinib, biological treatment, contact immunotherapy, cyclosporine, deuruxolitinib, JAK inhibitors, methotrexate, glucocorticoids, ritlecitinib , treatment, triamcinolone acetonide
Coverage in
Integrated with
